Organon & Co. (OGN) to Announce Quarterly Earnings on Tuesday

Organon & Co. (NYSE:OGN) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $0.87 per share and revenue of $1.5655 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.02 EPS. On average, analysts expect Organon & Co. to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Organon & Co. Stock Performance

Shares of OGN opened at $13.53 on Tuesday. The firm has a 50-day moving average price of $13.46 and a 200 day moving average price of $10.27. The firm has a market capitalization of $3.55 billion, a PE ratio of 14.54, a P/E/G ratio of 1.25 and a beta of 1.54. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.60.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, May 11th. Organon & Co.’s payout ratio is 8.60%.

Analysts Set New Price Targets

OGN has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, July 13th. BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and upped their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $11.40.

Insider Transactions at Organon & Co.

In other news, SVP Lynette Holzbaur bought 26,448 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were purchased at an average cost of $13.35 per share, with a total value of $353,080.80. Following the completion of the acquisition, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. The trade was a 100.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.62% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC boosted its position in shares of Organon & Co. by 105.2% during the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Balyasny Asset Management L.P. lifted its stake in Organon & Co. by 102.1% during the third quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock valued at $23,925,000 after purchasing an additional 1,131,941 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after buying an additional 801,307 shares in the last quarter. BNP Paribas Financial Markets grew its position in Organon & Co. by 335.8% in the third quarter. BNP Paribas Financial Markets now owns 957,667 shares of the company’s stock worth $10,228,000 after buying an additional 737,935 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Organon & Co. by 38.1% in the fourth quarter. Invesco Ltd. now owns 2,222,248 shares of the company’s stock valued at $15,934,000 after buying an additional 613,352 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.